NCT04607122View on ClinicalTrials.gov

Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

July 22, 2023

Conditions

Atrial FibrillationCardiac Surgery

Interventions

DRUG

Landiolol

Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.

DRUG

Saline

Continuous infusion of saline solution at the same rate as landiolol infusion.

Trial Locations (3)

91300

Hôpital Privé Jacques Cartier, Massy

92200

CMC Ambroise Paré, Neuilly-sur-Seine

93200

Centre Cardiologique du Nord, Saint-Denis

All Listed Sponsors

lead

CMC Ambroise Paré

OTHER

NCT04607122 - Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery | Biotech Hunter | Biotech Hunter